Murine models involving a combination of exposures to allergens and cigarette smoke (CS)
Strain | Experimental method | Key features of model | First author [ref.] |
BALB/c WT | 3 weeks of CS (5 days·week−1, 5 cigarettes for 7 min, 4 times·day−1) concurrent with OVA challenge via aerosol for 7 min, 4 times·day−1 |
| Moerloose [167] |
BALB/c WT | 3 weeks of HDM intranasally (5 days·week−1) followed by 2 weeks of concurrent HDM+CS (5 days·week−1, 12 cigarettes for 50 min, 1 or 2 times·day−1) |
| Botelho [168] |
C57BL/6 WT and CD44 deficient | 3 weeks of CS (5 days·week−1, 5 cigarettes 3 times·day−1) with HDM intranasally once per week at the end of CS exposure |
| Kumar [169] |
BALB/c WT | Triple OVA, cockroach antigen, and HDM intraperitoneally on days 0, 14, and 21 followed by 6 weeks of allergen challenge concurrent with CS (5 days·week−1, 4 cigarettes·day−1) |
| Tilp [170] |
C57BL/6J WT | LPS intranasally at days 0 and 14 followed by 10 weeks of CS (6 days·week−1, 9 cigarettes for 2 h, 2 times·day−1) |
| Shu [171] |
BALB/c WT | OVA intraperitoneally on days 0 and 14. OVA aerosol administered daily from days 24 to 41 in conjunction to CS (15 cigarettes for 40 min, 2 times·day−1) |
| Xia [172] |
WT: wild-type; OVA: ovalbumin; Ig: immunoglobulin; BALF: bronchoalveolar lavage fluid; IFN: interferon; IL: interleukin; HDM: house dust mite; VCAM-1: vascular cell adhesion molecule-1; TNF: tumour necrosis factor; CXCL1: C-X-C motif chemokine ligand 1; LPS: lipopolysaccharide; AHR: airway hyperresponsiveness; HDAC2: histone deacetylase 2; Akt: protein-kinase B.